Stemcentrx's Rova-T leads to responses

Data presented at the World Conference on Lung Cancer showed that Rova-T rovalpituzumab tesirine from Stemcentrx Inc. (South San Francisco, Calif.) led to an overall response rate of 44% among 16 small cell lung cancer (SCLC) patients expressing a delta-like protein 3 ( DLL3) biomarker in a Phase I trial.

Seven of 32 total evaluable SCLC patients had partial responses after treatment with the maximum tolerated dose of Rova-T, while 17 had stable disease. All seven responders and eight of those with stable disease had the biomarker. The trial studied Rova-T in patients with progressive SCLC who had previously received one or two lines of therapy. ...